Research programme: IL4/13 pathway transcription factor degraders - Kymera Therapeutics
Latest Information Update: 30 Jun 2023
At a glance
- Originator Kymera Therapeutics
- Class Anti-inflammatories; Antiasthmatics; Antidementias; Small molecules
- Mechanism of Action Transcription factor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Asthma; Chronic obstructive pulmonary disease; Eosinophilic oesophagitis
Most Recent Events
- 16 May 2023 Early research in Alzheimer's disease in USA (unspecified route), prior to May 2023 (Kymera Therapeutics pipeline, May 2023)
- 16 May 2023 Early research in Asthma in USA (unspecified route), prior to May 2023 (Kymera Therapeutics pipeline, May 2023)
- 16 May 2023 Early research in Chronic obstructive pulmonary disease in USA (unspecified route), prior to May 2023 (Kymera Therapeutics pipeline, May 2023)